Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2023 May 30;81(21):2075-2085.
doi: 10.1016/j.jacc.2023.02.052.

Improved Outcomes After Pulmonary Valve Replacement in Repaired Tetralogy of Fallot

Jouke P Bokma  1 , Tal Geva  2 , Lynn A Sleeper  2 , Ji Hae Lee  2 , Minmin Lu  2 , Tehila Sompolinsky  2 , Sonya V Babu-Narayan  3 , Rachel M Wald  4 , Barbara J M Mulder  1 , Anne Marie Valente  5
Affiliations
Free article
Multicenter Study

Improved Outcomes After Pulmonary Valve Replacement in Repaired Tetralogy of Fallot

Jouke P Bokma et al. J Am Coll Cardiol. .
Free article

Abstract

Background: The impact of pulmonary valve replacement (PVR) on major adverse clinical outcomes in patients with repaired tetralogy of Fallot (rTOF) is unknown.

Objectives: The purpose of this study was to determine whether PVR is associated with improved survival and freedom from sustained ventricular tachycardia (VT) in rTOF.

Methods: A PVR propensity score was created to adjust for baseline differences between PVR and non-PVR patients enrolled in INDICATOR (International Multicenter TOF Registry). The primary outcome was time to the earliest occurrence of death or sustained VT. PVR and non-PVR patients were matched 1:1 on PVR propensity score (matched cohort) and in the full cohort, modeling was performed with propensity score as a covariate adjustment.

Results: Among 1,143 patients with rTOF (age 27 ± 14 years, 47% PVR, follow-up 8.3 ± 5.2 years), the primary outcome occurred in 82. The adjusted HR for the primary outcome for PVR vs no-PVR (matched cohort n = 524) was 0.41 (95% CI: 0.21-0.81; multivariable model P = 0.010). Full cohort analysis revealed similar results. Subgroup analysis suggested beneficial effects in patients with advanced right ventricular (RV) dilatation (interaction P = 0.046; full cohort). In patients with RV end-systolic volume index >80 mL/m2, PVR was associated with a lower primary outcome risk (HR: 0.32; 95% CI: 0.16-0.62; P < 0.001). There was no association between PVR and the primary outcome in patients with RV end-systolic volume index ≤80 mL/m2 (HR: 0.86; 95% CI: 0.38-1.92; P = 0.70).

Conclusions: Compared with rTOF patients who did not receive PVR, propensity score-matched individuals receiving PVR had lower risk of a composite endpoint of death or sustained VT.

Keywords: cardiovascular magnetic resonance imaging; congenital heart disease; pulmonary valve replacement; tetralogy of Fallot.

PubMed Disclaimer

Conflict of interest statement

Funding Support and Author Disclosures This work was supported in part by National Institutes of Health/NLHBI/CCHMC 2UO1HL098147-12 and the Alexander S. Nadas Chair at Harvard Medical School (to Dr Geva), the Lerner Research Award and the Sarah Marie Liamos Fund (to Dr Valente), British Heart Foundation EX/18/1/34296 (to Dr Babu-Narayan), the Canadian Institutes of Health Research MOP 119353 (to Dr Wald), and by the Amsterdam Cardiovascular Sciences (to Dr Bokma). The authors have reported that they have no relationships relevant to the contents of this paper to disclose.

Comment in

Publication types